PD1/PDL1 expression
Showing 1 - 25 of >10,000
SOX2 & PDL1 Expression on Urinary Bladder Carcinoma
Not yet recruiting
- Urinary Bladder Neoplasm
- (no location specified)
Jun 17, 2022
Acute Lymphoblastic Leukemia in Pediatric Trial in Sohag (flow cytometric immunophynotyping)
Not yet recruiting
- Acute Lymphoblastic Leukemia in Pediatric
- flow cytometric immunophynotyping
-
Sohag, EgyptSohag University Hospital
Jun 19, 2022
Lung Cancer, Mesothelioma Trial in Orbassano (niraparib and dostarlimab)
Recruiting
- Lung Cancer
- Mesothelioma
- niraparib and dostarlimab
-
Orbassano, Turin, ItalyAOU San Luigi- Department of Oncology
Oct 6, 2021
HIPEC Combined With PD1/PDL1 Inhibitor for Gastric Cancer With
Not yet recruiting
- Gastric Cancer
- Observational
- (no location specified)
Dec 13, 2022
PDL1 In Primary Colorectal Carcinoma and Its Prognostic Impact
Not yet recruiting
- PDL1- Colorectal Carcinoma
- (no location specified)
Jan 11, 2023
PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC
Recruiting
- Non-small Cell Lung Cancer
-
Monza, ItalyASST-Monza Ospedale San Gerardo
Jun 9, 2022
Circulating Tumor Cells in Non-small Cell Lung Cancer
Recruiting
- Lung Cancer
- blood sample collection for CTC and MDSC analysis
-
Toulouse, FranceLarrey Hospital
Nov 18, 2020
SCLC,Extensive Stage Trial in Changchun (AK104 IV infusion;Chiauranib oral)
Not yet recruiting
- SCLC,Extensive Stage
- AK104 IV infusionï¼›Chiauranib oral
-
Changchun, Jilin, ChinaJilin Province Cancer Hospital
Aug 16, 2022
Skin Health and Quality of Life in Patients Receiving
Not yet recruiting
- Lung Cancer
- +7 more
- EQ-5D-5L questionnaire
- +2 more
-
Roma, ItalyRoberto Iacovelli
May 17, 2023
NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)
Not yet recruiting
- Non-small Cell Lung Cancer
- +4 more
- MK-2870
- +2 more
- (no location specified)
Sep 15, 2023
Solid Tumor Malignancy, Hematologic Malignancy, Leukemia Trial run by the NCI (mrna 1273 injection)
Recruiting
- Solid Tumor Malignancy
- +4 more
- mRNA-1273
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 14, 2023
Cervical Cancer Trial in Wuhan (Recombinant humanized anti-PD-1 mAb injection, Cisplatin, Bevacizumab Injection)
Not yet recruiting
- Cervical Cancer
- Recombinant humanized anti-PD-1 monoclonal antibody injection
- +4 more
-
Wuhan, Hubei, ChinaTongji Hospital affiliated to Tongji Medical College of Huazhong
Nov 3, 2023
Breast Cancer Trial in Guangzhou (Chidamide Plus Toripalimab Plus Paclitaxel)
Recruiting
- Breast Cancer
- Chidamide Plus Toripalimab Plus Paclitaxel
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Feb 19, 2023
Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression = 1% and an STK11
Recruiting
- Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
-
Montpellier, France
- +7 more
Dec 19, 2022
Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT
Recruiting
- Lung Cancer Stage III
- Lung Cancer Stage IV
-
Brest, FranceChu Brest
Aug 16, 2023
PD1+T Cell Expression in Peripheral Blood for Cardiac Function
Recruiting
- PD1
- Acute Myocardial Infarction
- PD1+ T Cell Expression
-
Hangzhou, Zhejiang, ChinaThe Second Affiliated Hospital of Zhejiang University, School of
Feb 22, 2022
Cancer Head Neck, Metastatic Cancer, Metastatic Lung Cancer Trial in New Haven (adnectin 18F-BMS-986192 Head and Neck Cancer,
Not yet recruiting
- Cancer Head Neck
- +2 more
- adnectin 18F-BMS-986192 Head and Neck Cancer
- adnectin 18F-BMS-986192 Brain Metastases
-
New Haven, ConnecticutYale University PET Center
Oct 10, 2022
Urothelial Carcinoma Trial in Ann Arbor (Pembrolizumab, Abraxane)
Active, not recruiting
- Urothelial Carcinoma
-
Ann Arbor, MichiganUniversity of Michigan Comprehensive Cancer Center
Dec 15, 2021
Hepatocellular Carcinoma Trial in Yichang (Sintilimab)
Recruiting
- Hepatocellular Carcinoma
-
Yichang, Hubei, ChinaDepartment of Medical Oncology, Central Hospital of Yichang City
Sep 1, 2023
NSCLC Trial (Phase I - Mirdametinib - Level 1, Phase II - Mirdametinib, Phase I - Mirdametinib - Level 2)
Not yet recruiting
- Non-Small Cell Lung Cancer
- Phase I - Mirdametinib - Level 1
- +4 more
- (no location specified)
Jul 7, 2023
Programmed Death Ligand-1 in Nasopharyngeal and Hyypopharyngeal
Not yet recruiting
- Nasopharyngeal and Hypopharyngeal Carcinoma
- immunohistochemical
-
Sohag, EgyptSohag University Hospital
Oct 23, 2022
Hematopoietic and Lymphoid Cell Tumor, Malignant Solid Tumor Trial (radiation, biological, procedure)
Withdrawn
- Hematopoietic and Lymphoid Cell Neoplasm
- Malignant Solid Neoplasm
- Copper Cu 64-DOTA-pembrolizumab
- +2 more
- (no location specified)
Jun 7, 2022
Head and Neck Squamous Cell Carcinoma, Magnetic Resonance Imaging, Neoadjuvant Therapy Trial in Guangzhou
Recruiting
- Head and Neck Squamous Cell Carcinoma
- +2 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen Memorial Hospital
Jul 27, 2023
Muscle Invasive Bladder Cancer, HER2 Expression, Radiotherapy Trial in Shanghai (Disitamab Vedotin and Toripalimab)
Recruiting
- Muscle Invasive Bladder Cancer
- +4 more
- Disitamab Vedotin and Toripalimab
-
Shanghai, Shanghai, ChinaRenji Hospital, School of Medicine, Shanghai Jiao Tong Universit
Jul 31, 2023
PD-L1 in Pancreatic Ductal Adenocarcinoma
Recruiting
- Pancreatic Adenocarcinoma
-
Sohag, EgyptFaculty of Medicine, Sohag University
Jan 27, 2022